Axsome Therapeutics (NASDAQ:AXSM) Insider Sells $1,368,150.00 in Stock

Key Points

• Insider sale: Ari Maizel sold 7,500 shares at an average price of $182.42 for a total of $1,368,150, cutting his stake by 50% (SEC filing).
• Earnings and outlook: Axsome beat EPS and revenue estimates (reported ($0.56) EPS and $196M revenue, +65% y/y) but remains unprofitable with negative ROE and net margin, while analysts maintain a "Moderate Buy" consensus with an average target of $218.06 (UBS raised its target to $259).
• Stock and ownership: Shares traded down about 2% to $182.72 (12‑month range $96.09–$191.50) with a market cap near $9.35B and roughly 81.5% of the stock held by institutions.

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) insider Ari Maizel sold 7,500 shares of the stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $182.42, for a total value of $1,368,150.00. Following the completion of the transaction, the insider owned 7,500 shares in the company, valued at approximately $1,368,150. The trade was a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Axsome Therapeutics Stock Down 2.0%

Shares of AXSM traded down $3.70 during mid-day trading on Thursday, reaching $182.72. The company's stock had a trading volume of 418,867 shares, compared to its average volume of 557,864. Axsome Therapeutics, Inc. has a 12-month low of $96.09 and a 12-month high of $191.50. The stock has a market cap of $9.35 billion, a PE ratio of -49.52 and a beta of 0.48. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.55 and a quick ratio of 1.48. The company's 50 day moving average is $170.28 and its 200 day moving average is $159.70.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its quarterly earnings data on Monday, February 23rd. The company reported ($0.56) EPS for the quarter, beating analysts' consensus estimates of ($0.70) by $0.14. Axsome Therapeutics had a negative return on equity of 232.61% and a negative net margin of 28.69%.The business had revenue of $196.00 million for the quarter, compared to the consensus estimate of $191.33 million. The business's revenue was up 65.0% on a year-over-year basis. Equities analysts anticipate that Axsome Therapeutics, Inc. will post -1.25 EPS for the current fiscal year.

Institutional Trading of Axsome Therapeutics

A number of hedge funds have recently added to or reduced their stakes in AXSM. Wellington Management Group LLP lifted its position in Axsome Therapeutics by 84.1% during the 3rd quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company's stock worth $162,082,000 after acquiring an additional 609,516 shares during the period. Norges Bank acquired a new stake in Axsome Therapeutics during the 4th quarter worth approximately $90,490,000. Price T Rowe Associates Inc. MD lifted its position in Axsome Therapeutics by 45.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,509,870 shares of the company's stock worth $275,763,000 after acquiring an additional 472,422 shares during the period. Invesco Ltd. lifted its position in Axsome Therapeutics by 73.3% during the 3rd quarter. Invesco Ltd. now owns 990,557 shares of the company's stock worth $120,303,000 after acquiring an additional 419,008 shares during the period. Finally, Adage Capital Partners GP L.L.C. lifted its position in Axsome Therapeutics by 831.3% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 447,000 shares of the company's stock worth $46,662,000 after acquiring an additional 399,000 shares during the period. 81.49% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. UBS Group upped their target price on Axsome Therapeutics from $251.00 to $259.00 and gave the company a "buy" rating in a research report on Friday, April 10th. Weiss Ratings reissued a "sell (d-)" rating on shares of Axsome Therapeutics in a research report on Monday. Jefferies Financial Group set a $215.00 target price on Axsome Therapeutics in a research report on Monday, February 23rd. Robert W. Baird set a $209.00 target price on Axsome Therapeutics in a research report on Tuesday, January 13th. Finally, Piper Sandler upped their target price on Axsome Therapeutics from $148.00 to $223.00 and gave the company an "overweight" rating in a research report on Friday, January 16th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $218.06.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome's pipeline includes several late-stage and approved product candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.